TWDBTaiwan Manufacturer Database 中文

ANBOGEN THERAPEUTICS, INC.

安邦生技股份有限公司

Leave your email for change alerts (optional)

My watchlist →

2019Founded
NT$1.1BPaid-in capital
0Plants
3Patents
< NT$20MRevenue band (est.)
Unified Business No.
82833776
Industry
Tobacco Manufacturing (1,186)
Listing
Emerging stock (TPEx) (359) 7784
Founded
2019-04-03
Paid-in capital
NT$ 1,145,133,597
Phone
02-89798616
Website
https://anbogen.com/
Exporter
Yes — registered with the Trade Administration
Annual revenue band
< NT$20M estimated
Ownership
Individually held
Representative tenure
In office since 2021-01 (5 yrs); last handover 2021-01 (same surname)
Growth & profitability
Revenue 2026-09 YoY —, year-to-date —
Compliance record
Labour Standards Act penalties: 1 case(s) in 5 years, latest 2023-07-10, fines NT$ 50,000 (Art. 24) — matched by company name

Processes & materials 1

Patents 3

  • 2025 Crystalline form of (E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide
  • 2025 Pharmaceutical kit for treating colorectal cancer and use thereof
  • 2023 (S,E)-4-(dimethylamino)-N-(3-(4-(2-hydroxy-1-phenethylamino)-6-phenyl

Similar companies 10

Open in advanced filters →